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The objectives of this study were to analyze in-hospital adverse drug events 
(ADEs) in Portuguese public hospitals, and their association with mortality 
and the duration of hospitalization. We analyzed an administrative database 
containing the registration of all hospitalizations occurring in Portuguese pub-
lic hospitals in 2013-2015. ADEs were identified using the codes E850-858.9 
and E930-949.9 from ICD-9-CM. We identified all episodes with registration 
of in-hospital ADE and we compared them with a random sample of an equal 
number of episodes with no events recorded. A total of 3,041,443 cases were 
analyzed, 60,521 presented at least one ADE from which 17,213 occurred in 
hospital context. The most frequent drug classes associated with ADE were the 
antineoplastics/immunosuppressant drugs, antibiotics and steroids. Patient 
characteristics associated with a greater occurrence of in-hospital ADEs (all 
with p < 0.001) were medical admissions (OR = 1.29), the diagnosis – my-
eloid leukaemia (OR = 18.63), nephrotic syndrome (OR = 15.75), pneumonia 
(OR = 1.33) –, a higher number of secondary diagnoses (OR = 1.27), and in-
creased duration of hospital stay (OR = 1.06). Hospitalizations with records of 
in-hospital ADEs presented a significantly higher mortality (9.6% vs. 4.5) and 
duration of hospitalization (22.6 vs. 6.4 days). ADEs were shown to be directly 
associated with an increase in the duration of hospital stay of 8.18 days. This 
study adds some interesting insights related to the most frequent drug classes 
and patient characteristics that can influence the frequency of ADEs in Portu-
guese public hospitals and also the burden of injury resulting from them.
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Introduction
An adverse drug event (ADE) is defined by the World Health Organization (WHO) as a harmful and 
involuntary harm arising from the use of a drug and which occurs due to preventive health care 
administered to the patient for diagnosis, therapy, or the modification of physiological functions 1. 
This definition comprises adverse drug reaction (ADR) and accidental poisoning by drugs (AP), as 
long as these result in harm.
ADEs are one of the main concerns regarding the patient’s safety, because they represent one of 
the most frequent worldwide causes of harm, the main consequence of which is the death of thou-
sands of patients per year 2. To address these problems, WHO launched the third Global Patient Safety 
Challenge, Medication Without Harm, with the overall goal “to reduce medication errors by 50% in the next 
five years” 2.
International studies show that between 0.7% and 21.3% of hospitalized patients have an 
ADE 3,4,5,6,7. These events, besides significantly impacting mortality and morbidity, are also associated 
with an increase in health costs 5,8. On a global level, annual costs have been estimated at 42 billion 
dollars, representing approximately 1% of total health expenses 2.
In Portugal, the evidence available also points to a high rate of in-hospital ADEs. A study carried 
out in nine acute care public hospital centers, using the clinical record review methodology, identi-
fied an incidence of 12.5% adverse events in the year 2013, of which 9.8% were associated with drug 
errors, representing the third most frequent adverse event 9. According to other studies carried out 
in Portuguese public hospitals, using administrative data, 1.46% and 1.88% of hospitalized patients 
showed at least one ADE 10,11.
Given the previously mentioned facts, it becomes apparent that studies carried out in hospitals 
in a diverse range of countries have identified a high ADE frequency, with significant heterogeneity. 
As many of these events could be prevented, there is a growing interest in their effective identifica-
tion and the implementation of successful preventive strategies, with the aim of improving patient 
safety and enhancing hospital efficiency 4. The assessment of the clinical performance from health 
services and organizations is essential to move towards care quality excellence and to achieve a more 
efficient performance 12.
Adverse event frequency has been calculated based on different methodologies, using various 
data sources, including clinical record review, direct observation, analysis of incidents by reporting 
systems, systems based on administrative data, among others 13.
The use of administrative data, based on the International Classification of Diseases (ICD), as a 
support to monitoring adverse events occurring during hospitalization (in-hospital events) has gained 
increasing relevance in the past decade, because it requires less resources – economic and human, 
among others – and is readily available 14.
Nevertheless, analysis of adverse events through administrative data may detect events which 
have occurred before admission to hospital. The application of “present at admission” (PAA) coding 
has enabled a more reliable analysis of the adverse events occurring on the in-hospital stage, because 
it allows differentiation between the events present at the date of admission at hospital and the ones 
acquired during hospitalization 15. In this regard, it is important to emphasize that the PAA indicator 
was not contemplated in previous studies carried out in Portugal, based on administrative data.
Therefore, the underlying reasons motivating this study are as follows: in-hospital ADEs are 
clinically and economically relevant, the dimension of these adverse events in Portugal based on the 
PAA indicator is not yet known, and the authors are convinced that it is only possible to implement 
measures to improve the quality of the healthcare provided and to contribute to a greater efficiency 
of Portuguese hospitals if the adverse event dimension and its impacts are known.
In this regard, the objective we have defined for this study is to analyze ADEs which have occurred 
within the in-hospital period, and their impact on mortality and duration of hospitalization, from 
2013-2015, after PAA indicators were introduced.
IN-HOSPITAL ADVERSE DRUG EVENTS IN PORTUGUESE PUBLIC HOSPITALS 3
Cad. Saúde Pública 2020; 36(3):e00056519
Methods
Type of study
A retrospective observational cross-sectional study was carried out, using administrative data from 
all Portuguese public hospitals.
Data sources
We used the Portuguese hospital morbidity database (BDMH) for the 2013-2015 triennium. The 
selection of this period is due to the fact that the PAA indicator was only introduced into the BDMH’s 
clinical encoding in 2013. The years 2016, 2017 and 2018 were also not considered because, at the 
date of completion of this study, there was no final validation of the data available for these years.
This database aggregates data from all hospitalizations and outpatient episodes occurring in Por-
tuguese national health system hospitals, encoded in accordance with the ICD, 9th Revision, Clinical 
Modification (ICD-9-CM) and classified into diagnosis related groups. The ICD-10 has been used in 
Portuguese hospitals since 2017. For that reason, in this study, we used the ICD-9.
The criteria for the selection of the ADE codes were based on the literature analyzed 10,16,17,18. 
The in-hospital ADEs were identified on the BDMH using the E850-858.9 codes (50 codes) for AP 
and E930-949.9 codes (171 codes) for ADRs which were not present at the moment of admission. 
The application of the variable encoded PAA allowed us to differentiate the ADEs that were already 
present at the moment of admission in hospital from the ones acquired during the hospitalization.
The set of official data in this database was previously anonymized, thus waiving the need for 
informed consent and authorization from the ethics committee.
Statistical analyses
In a first stage, the episodes with at least one ADE occurring during hospitalization (in-hospital) 
were identified for the whole population under study. After that, we calculated the in-hospital ADE 
frequency associated with ADR and AP and identified the class of drugs most frequently associated 
with these events. In this stage, we included descriptive statistical measurements (absolute and rela-
tive frequencies mean).
In the second stage, we compared the in-hospital ADE episodes with a random sample of an equal 
number of episodes with no events recorded, with regard to the population’s characteristics, mortali-
ty, and the duration of stay at hospital. At first, a bivariable analysis was carried out, with the variables: 
age, gender, type of hospital admission (urgent vs. planned), type of treatment (surgical vs. medical), 
the most frequent six diagnoses for in-hospital ADE episodes, the number of secondary diagnoses, 
and the duration of stay. At this stage, in the bivariable analysis, we used Fisher’s exact test, the chi-
square test of independence, when comparing qualitative variables and Student’s t-distribution test 
for independent samples when comparing two groups of quantitative dependent variables. The sta-
tistically significant variables (p < 0.05) were included in the multivariable analysis.
To identify the characteristics of the population associated with the occurrence of in-hospital 
ADEs and to analyze the association of these events with mortality, we opted for a binary logistic 
regression analysis.
To assess the association of in-hospital ADE events with duration of stay, we opted for a multiple 
linear regression analysis.
The multivariable analysis results were displayed as odds ratio (OR) in the logistic regression and 
as a non-standard regression coefficient (B) in the linear regression with 95% confidence intervals 
(95%CI). Values of p < 0.05 were deemed statistically significant.
The statistical analysis was carried out using SPSS for Windows, version 25.0 (https://www. 
ibm.com/).
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Results
Analysis of 3,041,443 episodes of patients hospitalized in Portuguese public hospitals for the period 
of 2013-2015 were carried out (Table 1). From these, 60,521 (2%) suffered from at least one ADE, of 
which 28.5% (17,213; 0.6% of the total episodes) occurred within the in-hospital framework. In-hospi-
tal ADE episodes increased gradually throughout the triennium, from 0.41% in 2013 to 0.65% in 2015.
Table 1 shows some descriptive statistics of the whole population and the total frequency of in-
hospital ADE distribution per age, gender, type of admission and treatment, principal diagnosis, and 
the mean number of secondary diagnoses.
The greatest proportion of in-hospital ADE episodes (54.9%) occurred in patients aged 65 years 
or over.
The mean number of secondary diagnoses was much higher for in-hospital ADE episodes (11.7% 
vs. 3.9%).
In certain episodes, several ADEs were recorded. Considering the multiple ADEs occurring 
for each episode, the total number of events detected was 70,244, from which 19,260 (27%) were 
in-hospital.
Table 1
Descriptive statistics of the whole population and the total frequency of in-hospital adverse drug events (ADEs) 
distributions per age, gender, type of admission and treatment, principal diagnosis and the mean number of secondary 
diagnoses. 
Whole population In-hospital ADE
n (%) n (%)
Total 3,041,443 (100.0) 17,213 (0.6)
Age (years)
< 65 1,738,251 (57.1) 7,755 (45.1)
≥ 65 1,303,192 (42.9) 9,458 (54.9)
Mean age 53.6 62
Gender
Male 1,391,747 (45.8) 8,534 (49.6)
Female 1,649,696 (54.2) 8,679 (50.4)
Type of hospital admission
Urgent 1,815,567 (59.7) 12,590 (73.1)
Planned 1,225,876 (40.3) 4,623 (26.9)
Type of treatment
Surgical 929,949 (30.6) 4,034 (23.4)
Medical 2,111,494 (69.4) 13,179 (76.6)
Principal diagnosis *
486 92,347 (3.0) 995 (5.8)
581.1 22,627 (0.7) 699 (4.1)
428.0 44,027 (1.4) 571 (3.3)
20.500 2,299 (0.1) 462 (2.7)
434.91 41,077 (1.4) 440 (2.6)
038.9 20,657 (0.7) 311 (1.8)
Secondary diagnoses
Mean 4.3 11.7
* ICM-9-CM codes: 486 Pneumonia, organism unspecified; 581.1 Nephrotic syndrome with lesion of membranous 
glomerulonephritis; 428.0 Congestive heart failure, unspecified; 20.500 Acute myeloid leukaemia, without mention  
of having achieved remission; 434.91 Cerebral artery occlusion, unspecified with cerebral infarction;  
038.9 Unspecified septicemia.
IN-HOSPITAL ADVERSE DRUG EVENTS IN PORTUGUESE PUBLIC HOSPITALS 5
Cad. Saúde Pública 2020; 36(3):e00056519
Regarding the nature of in-hospital ADEs, 19,154 (99.4%) were associated with ADR E-codes and 
106 (0.6%) with AP E-codes. Figures 1 and 2 illustrate the most frequent classes of drugs detected in 
in-hospital ADEs-ADR E-codes and AP E-codes, respectively.
To analyze the characteristics of the population associated with a higher incidence of in-hospital 
ADEs, as well as the association of these events with mortality and hospitalization duration, we com-
pared in-hospital ADE episodes (17,213) with a random sample of an equal number of episodes with 
no ADEs.
Characteristics of the population associated with the occurrence of in-hospital ADEs
Table 2 shows some descriptive statistics of the in-hospital ADE episodes (17,213) and the random 
sample of an equal number of episodes with no ADEs. In these table, we also show the results of the 
bivariable and multivariable (multiple logistic regression) analyses, which aimed to identify patient 
characteristics independently associated with in-hospital ADEs.
In the bivariable analysis some patient characteristics with statistical significance (p < 0.001) were 
associated with a large frequency of in-hospital ADEs: aged over 65 years, male, admissions coded as 
urgent, medical diagnostic-related group type, top six principal diagnoses, and a greater number of 
secondary diagnoses. In these analyses, we also observed that as the number of hospitalization days 
grew, so did the probability of occurrence of an in-hospital ADE.
In the multivariable analysis (multiple logistic regression) we observed that ages 65 or older did 
not show a greater probability for the occurrence of in-hospital ADEs (OR = 0.69; p < 0.001). The 
characteristics observed in those patients showing a higher probability of in-hospital ADE occur-
rence were, independently, associated with medical treatments (OR = 1.29; p < 0.001), main diagno-
ses – pneumonia, unspecified organism (OR = 1.33; p < 0.001), nephrotic syndrome with lesion of 
membranous glomerulonephritis (OR = 15.75; p < 0.001), acute myeloid leukaemia without mention 
of having achieved remission (OR = 18.63; p < 0.001) –, and a greater number of secondary diagnoses 
(OR = 1.27; p < 0.001).
Figure 1
Distribution of five most frequent in-hospital adverse drug reactions (ADRs).
E933.1: Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use; E930.8: Other 
specified antibiotics causing adverse effects in therapeutic use; E932.0: Adrenal cortical steroids causing adverse effects 
in therapeutic use; E934.2: Anticoagulants causing adverse effects in therapeutic use; E944.4: Other diuretics causing 
adverse effects in therapeutic use.
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Figure 2
Distribution of five most frequent in-hospital accidental poisoning by drugs (AP).
E856: Accidental poisoning by antibiotics; E853.2: Accidental poisoning by benzodiazepine-based tranquilizers; E858.2: 
Accidental poisoning by agents primarily affecting blood constituents; E858.3: Accidental poisoning by agents primarily 
affecting cardiovascular system; E855.5: Accidental poisoning by sympathomimetics [adrenergics].
Table 2
Bivariable and multivariable analyses between in-hospital adverse drug events (ADEs) and patient characteristic.
In-hospital ADE Without ADE Bivariable analysis Multiple logistic regression
n (%) n (%) p-value OR 95%CI p-value OR 95%CI
Age in years (ref.: < 65) ≥ 65 9,458 (56.7) 7,212 (43.3) < 0.001 1.69 1.62-1.77 < 0.001 0.69 0.65-0.73
Gender (ref.: Male) Female 8,679 (48.1) 9,347 (51.9) < 0.001 0.86 0.82-0.89 0.111 1.06 0.99-1.11
Type of admission (ref.: Urgent) Planned 4,623 (39.8) 7,007 (60.2) < 0.001 0.54 0.51-0.56 0.990 1.000 0.93-1.107
Type of treatment (ref.: Surgical) Medical 13,179 (52.7) 11,813 (47.3) < 0.001 1.49 1.42-1.57 < 0.001 1.29 1.12-1.38
Principal diagnosis
486 (ref.: No) Yes 995 (66.9) 492 (33.1) < 0.001 2.09 1.87-2.33 < 0.001 1.33 1.17-1.52
581.1 (ref.: No) Yes 699 (86.3) 111 (13.7) < 0.001 6.52 5.33-7.98 < 0.001 15.75 12.76-19.45
428.0 (ref.: No) Yes 571 (69.5) 251 (30.5) < 0.001 2.32 2.00-2.69 0.302 1.099 0.92-1.32
205.00 (ref.: No) Yes 462 (98.5) 7 (1.5) < 0.001 67.79 32.12-143.04 < 0.001 18.63 8.71-39.85
434.91 (ref.: No) Yes 440 (63.7) 251 (36.3) < 0.001 1.77 1.52 -2.07 0.065 0.833 0.69-1.01
038.9 (ref.: No) Yes 311 (76.6) 95 (23.4) < 0.001 3.32 2.63-4.18 < 0.001 0.53 0.40-0.71
Secondary diagnosis [M (SD)] 11.7 (7.1) 3.9 (4.3) < 0.001 1.31 1.30-1.32 < 0.001 1.27 1.26-1.28
Duration of hospitalization in days 
[M (SD)]
22.6 (29) 6.4 (10.3) < 0.001 1.11 1.10-1.12 < 0.001 1.06 1.06-1.06
95%CI: 95% confidence interval; M: mean; OR: odds ratio; Ref.: reference category; SD: standard deviation.
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Regarding the number of hospitalization days, we also observed that these had increased, so had 
the probability of the occurrence of adverse events (OR = 1.06; p < 0.001).
Association between in-hospital ADE, mortality, and duration of stay
The episodes of in-hospital ADEs, in the bivariable analysis, showed a proportion of deaths signifi-
cantly higher when compared with episodes with no ADE (9.6 vs. 4.5; p < 0.001). However, in the 
multivariable analysis (multiple logistic regression), we did not observe an association between in-
hospital ADE and increased mortality (OR = 0.73; p < 0.001).
Regarding the duration of stay, we observed that in-hospital ADE episodes are linked to a much 
higher mean of hospitalization days, when compared with episodes with no events (22.6 and 6.4 
days, respectively; p < 0.001). In the multivariable analysis (linear regression), we determined that 
in-hospital ADE episodes were independently associated with an increase on the duration of stay of 
8.18 days (B = 8.18; p < 0.001).
Discussion
The study of 3,041,443 hospitalization episodes, registered for the period under analysis, revealed that 
17,213 (0.6%) showed at least one ADE within the in-hospital framework. Since most available studies 
based on administrative data do not differentiate between the events present at the time of admission 
and the ones occurring within the hospital framework, it is difficult to make a comparison. On the 
one hand, the studies available used different methodologies, different populations, and different ICD 
codes to identify in-hospital ADEs.
However, this study’s results were similar to the one carried out in Australia by Parikh et al. 7, 
which showed a 0.7% in-hospital ADE frequency.
The studies from Amelung, et al. 4 and Rottenkolber et al. 19 showed a higher percentage of in-
hospital ADEs (6.6% and 3.8%, respectively). In the case of the study by Amelung et al. 4, the authors 
considered that the high frequency of events was associated with the fact that the study’s period 
covered a stage in which the encoding quality was strongly connected to German diagnosis related 
groups-based reimbursement. Regarding the study by Rottenkolber et al. 19, the in-hospital ADE fre-
quency was obtained through a secondary diagnosis, which may result in higher results because the 
secondary diagnosis was already present at the moment of admission.
Other studies carried out in different countries also showed a higher ADE frequency, between 
3.22% and 6.28% 5,20, but these studies included both the ADE present at the time of admission and 
the in-hospital ones.
The most recent Portuguese studies, based on administrative data, showed an ADE frequency of 
between 1.46% and 1.88% 10,11,21, but they also did not differentiate between the ADE present at the 
time of admission and the in-hospital one.
In this study, we observed an increased in-hospital ADE frequency: from 0.41% in 2013 to 0.65% 
in 2015. Nevertheless, this situation must be carefully analyzed because these results may reflect a real 
increase in the in-hospital ADE frequency, but they may also be associated with greater awareness 
of hospitals about the patients’ safety and, subsequently, better practice regarding the recording and 
encoding of these events. In a study carried out at nine Portuguese acute care hospital centers 9, it was 
observed that the adverse event frequency was higher in the accredited hospitals (13.7% vs. 11.2%). A 
reasonable explanation for these results, according to the authors, may be associated with the fact that 
the accredited hospitals display a greater awareness of the patient’s safety and have a systemic practice 
of data recording and analysis.
Regarding the nature of the events, we determined that 99.4% of the E-codes were associated with 
ADR and 0.6% with AP. These results are not surprising and are in line with the study by Hougland et 
al. 22, which showed that the codes associated with AP were more prone to detect the ADE caused at 
the moment of admission than the ones which occurred within an in-hospital framework, contrary 
to the codes associated with ADR.
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The huge difference between the AP and ADR E-code frequency may reflect the reality of the 
in-hospital setting or may be associated with several reasons, among which are under-recording and 
under-encoding.
According to Wachter 23, records of adverse events may vary in accordance with the institutional 
culture (punitive or not) and with the individual responsibility of each professional.
AP E-codes are associated with drug errors that may be prevented, while ADR E-codes are not 
always preventable 16. This difference at the level of an adverse event’s prevention could influence the 
recording/notification of clinical records of the events which occurred.
Regarding the class of drugs associated with in-hospital ADEs, we observed that the antineo-
plastic/immunosuppressant drugs were among the most frequent causes of events, similar to other 
studies carried out at a national and international levels 4,5,10,18. Antibiotics, adrenal cortical steroids, 
anticoagulants, and diuretics not elsewhere specified were also included among the five most frequent 
causes of ADEs. Similar results were found by several studies carried out in the last five years 5,7,8,10,24.
A possible explanation for these results may be associated with the evidently known effects deriv-
ing from the toxicity of these drugs – for instance, antineoplastic drugs and neutropenia, steroids and 
hyperglycemia, anticoagulants and haemorrhage 5. Clarity about adverse reactions to these drugs may 
facilitate the recording of events and the encoding process 5.
Population characteristics associated with the occurrence of in-hospital ADEs
Age groups of 65 years and older showed a higher frequency of in-hospital ADEs, similar to other 
international and national studies 3,5,7,8,10,11,24. However, in the multivariable analysis, we observed 
that age was not an independent risk factor in the occurrence of these events. A possible explana-
tion for this result is the fact that age itself is not a risk factor for the occurrence of these events, but 
rather all the characteristics associated with older patients are risk factors. Older patients become a 
particularly vulnerable group for the occurrence of ADEs because, due to the natural physiological 
alterations associated with old age, there is a higher possibility of suffering from a higher number of 
comorbidities and severe illnesses, leading to the need to receive multiple treatments (highly complex 
in certain situations), polymedication, and to remain hospitalized for long periods 25,26,27,28,29.
The aging population and the increase of associated comorbidities, as well as increased treatment 
complexity and non-adjustment of the available funds for the exigencies of the health domain, estab-
lish a new potential risk for mistakes and harm to the patients and, subsequently, a challenge for the 
patient’s safety 25. Given these facts, it is clear that health professionals and administrators need to be 
particularly focused on ADE prevention strategies for this population subgroup.
While analyzing patients’ characteristics associated with the occurrence of in-hospital ADEs, we 
also observed that as the number of secondary diagnoses (complications and/or comorbidities) grew, 
so did, independently, the probability of in-hospital ADEs. These results are in line with several stud-
ies identifying a link between multiple comorbidities and the occurrence of ADEs 5,10,11. On the other 
hand, the existence of a larger number of complications and/or comorbidities is also associated with 
multiple medications, which, in turn, is also a risk factor for the occurrence of ADEs 3,24.
In this study, we verified that an increase in the duration of stay at hospital is independently asso-
ciated with a greater probability for the occurrence of in-hospital ADEs. These results are in line with 
a meta-analysis carried out by Laatikainen et al. 3 for the period between 2000 and 2016, in which 
the increase of the periods of stay was identified as one of the main risk factors for the occurrence 
of ADEs. Hauck & Zhao 30, when analyzing the risk factors and the incidence of adverse events, also 
observed that the duration of stay increased the possibility of adverse events at magnitudes compa-
rable with other risk factors, such as age, urgent admission, or multiple comorbidities.
Association between in-hospital ADE, mortality, and duration of stay
In-hospital ADE episodes showed a significantly higher mortality rate when compared with episodes 
with no ADE (9.6% vs. 4.5); however, in logistic regression we did not observe any association between 
the events and increased mortality (OR = 0.73). Similar results were found by the Portuguese study 
led by Sousa Pinto et al. 11, in which, when comparing the mortality proportion for episodes with and 
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without ADE according to the characteristics of the patients and of the episodes, confirmed that the 
mortality was lower in the group with ADEs.
These results, regarding the association between in-hospital ADE and mortality, contrast with the 
results found in other studies based on clinical record review which show an association between in-
hospital ADEs and the mortality increase 31,32.
A possible explanation for the results of this study may be related to the fact that the most frequent 
events are not the most severe or that there is an under-recording and/or under-encoding of the most 
severe events. In the available BHMH data, there was no data about the severity of the encoded events; 
therefore, the proportion of the severe events encoded is unknown. On the other hand, the causes of 
death are also unknown, making it impossible to understand the death proportion associated with 
in-hospital ADEs.
Regarding the duration of hospitalization, we observed that in-hospital ADEs had a significant 
impact on the duration of stay and, subsequently, on the hospitals’ efficiency, because the presence of 
these types of events was directly associated with an increase of the duration of stay to 8.18 days with 
statistical significance. These results are similar to the results of Parikh et al. 7, which showed that the 
duration of stay was higher than seven days for patients presenting in-hospital ADEs. In other pub-
lished studies, it was also verified that the ADE leads to an extension of the duration of stay from 1.7 
to 6.7 days 4,5,8,10,11. This finding is extremely important because any increase in the duration of stay 
entails financial losses for the hospital, in addition to the personal and social impact for the patients 
and their families. Nevertheless, we cannot exclude the possibility of an extended duration of stay 
being at the origin of the occurrences of in-hospital ADEs.
This study presents some limitations; therefore, the results must be considered carefully. Firstly, 
there is incomplete information and possible filing errors within the BDMH. Secondly, one must 
consider the non-identification of some in-hospital ADEs, related to under-recording and under-
encoding problems. Thirdly, there is a lack of specific data in the BDMH, which could help explain 
some results found – specifically, the severity of the episodes, the severity of the ADEs encoded, and 
the events that could be prevented. Another limitation is the fact that this study does not include the 
potential number of medications confounder in the regression analysis. But it is well known that the 
number of medications is a consequence of the number of secondary diagnoses as well as the primary 
diagnosis and type of treatment. We have included all of these other variables in the multivariable 
regression model allowing us to conclude that some primary diagnosis as well as bigger number of 
secondary diagnoses and medical treatment are associated with more adverse events.
However, this study also presents strong points; of particular note is the analysis of the ADEs 
occurring during hospitalization, at a national level, for a period of three years. In addition, some 
strategies were adopted to reduce the effect of eventual biases of other independent variables. In par-
ticular, several multivariable analyses were carried out to identify the characteristics of the population 
associated with the occurrence of in-hospital ADEs and to analyze the association of these events with 
mortality and duration of stay.
Even though not all in-hospital ADEs may be prevented, this study contributes to improving the 
information available on in-hospital ADEs at a national level, therefore representing a base of knowl-
edge to support the decision-making process of the hospital administrators and health professionals 
concerning the prioritization of resources and the targeting of specific strategies for each risk group.
The strategies emerging from different international organizations are consensual in their con-
sideration that in order to minimize adverse events, it is crucial to improve procedures, use technol-
ogy, and build an organization culture of patient safety 33,34. In addition to the need for hospitals to 
be more efficient in implementing safety procedures aiming at preventing adverse events, it is also 
crucial to efficiently manage the duration of hospitalization.
For a better understanding of this issue, this study also reinforces the need to investigate, in detail, 
some areas, among which we highlight: analyzing preventable ADEs occurring within the in-hospital 
framework and their impact on the hospitals’ effectiveness and efficiency, analyzing in which phase 
of the drug’s circuit the preventable ADE occurs, and analyzing the severity level of the encoded in-
hospital ADEs and their association with mortality.
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Conclusions
This was the first study based in Portuguese hospital morbidity database that distinguishes between 
ADE present on admission and those occurring during hospital stay, with the application of the vari-
able encoded PAA.
In this study, we observed that 17,213 (0.6% of the total) of all Portuguese hospitalizations occur-
ring between 2013 and 2015 presented at least one occurrence of in-hospital ADEs. These episodes 
were independently associated with an increase in the duration of hospitalization.
Even though this study is only a small contribution to a large problem, in our view, it may help 
assist hospital administrators and health professionals to prioritize resources and target interven-
tions for each risk group, aiming to minimize adverse events and the resulting clinical and financial 
consequences.
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Resumo
O estudo teve como objetivos analisar os eventos 
adversos a medicamentos (EAMs) em hospitais pú-
blicos de Portugal e a associação com mortalidade 
hospitalar e tempo de internação. Foi analisada 
uma base de dados administrativos com regis-
tros de todas as internações em hospitais públicos 
portugueses entre 2013 e 2015. Os EAMs foram 
identificados com o uso dos códigos E850-858.9 
e E930-949.9 da CID-9-MC. Identificamos to-
dos os episódios com registro de EAM hospitalar 
e comparamos com uma amostra aleatória de um 
número igual de episódios, sem registro de even-
tos. Foram analisados 3.041.443 casos, dos quais 
60.521 apresentavam pelo menos um EAM, das 
quais 17.213 ocorreram no contexto hospitalar. 
As classes de drogas mais associadas aos EAMs 
foram antineoplásicos/imunossupressores, anti-
bióticos e corticosteroides. As características dos 
pacientes mais associadas aos EAMs (todas com 
p < 0,001) foram internações pela clínica médica 
(OR = 1,29), diagnóstico de leucemia mieloide 
(OR = 18,63), síndrome nefrótica (OR = 15,75) ou 
pneumonia (OR = 1,33), número maior de diag-
nósticos secundários (OR = 1,27) e maior tempo 
de internação (OR = 1,06). As hospitalizações com 
registro de EAM hospitalar mostraram mortalida-
de significativamente mais elevada (9,6% vs. 4,5) e 
maior tempo de internação (22,6 vs. 6,4 dias). Os 
EAMs mostraram associação direta com o tempo 
de internação hospitalar, aos 8,18 dias. O estudo 
traz contribuições interessantes relacionadas às 
classes farmacológicas mais frequentes e às carac-
terísticas dos pacientes que podem influenciar a 
frequência de EAMs nos hospitais públicos portu-
gueses e a consequente carga de morbidade.
Eventos Adversos; Classificação Internacional de 
Doenças; Hospitalização
Resumen
Los objetivos del estudio fueron analizar eventos 
adversos con medicamentos (EAMs) en hospitales 
públicos portugueses, así como su asociación con 
la mortalidad y la duración de la hospitalización. 
Analizamos una base de datos administrativa, que 
contenía el registro de todas las hospitalizaciones 
que se produjeron en hospitales públicos portugue-
ses desde 2013 a 2015. Los EAMs fueron identi-
ficados usando los códigos E850-858.9 y E930-
949.9 desde CIE-9-MC. Identificamos todos los 
episodios registrados de EAMs en hospitales y los 
comparamos con una muestra aleatoria de un nú-
mero igual de episodios sin eventos registrados. Se 
analizaron un total de 3.041.443 de casos, 60.521 
presentaron al menos un EAM de los 17.213 que 
se produjeron en un contexto hospitalario. Los 
tipos de medicamentos más frecuentes, asociados 
con EAM, fueron los antineoplásicos/inmunosu-
presores, antibióticos y esteroides. Las caracterís-
ticas del paciente, asociadas con una ocurrencia 
mayor de eventos adversos con medicamentos en 
hospitales, (todos con p < 0,001) fueron: admisio-
nes médicas (OR = 1,29); diagnóstico de leucemia 
mieloide (OR = 18,63), síndrome nefrítico (OR = 
15,75) o neumonía (OR = 1,33); un alto número 
de diagnósticos secundarios (OR = 1,27), así co-
mo una duración mayor en el ingreso hospitalario 
(OR = 1,06). Las hospitalizaciones con registros 
de EAMs en hospitales presentaron una mortali-
dad significativamente más alta (9,6% vs. 4,5), así 
como la duración de la hospitalización (22,6 vs. 
6,4 días). Los EAMs mostraron estar directamente 
asociados con el incremento en los ingresos hospi-
talarios a partir de los 8,18 días. Este estudio aña-
de algunos planteamientos interesantes, relaciona-
dos con los tipos de medicamentos más frecuentes 
y características de los pacientes, que pueden in-
fluenciar en la frecuencia de EAMs en hospitales 
públicos portugueses, así como también en la carga 
de las lesiones resultante de los mismos.
Evento Adverso; Clasificación Internacional de 
Enfermedades; Hospitalización
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